Clinical Trial Update: CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) [Phase 1]

View source ↗

Summary

Phase 1 trial update for CM93 in EGFR-modified recurrent glioblastoma; study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• CM93

Snippet

Sponsor: Crimson Biopharm Inc. | Conditions: Glioblastoma | Phase 1 | Status: NOT_YET_RECRUITING